# OnCo record uveal-melanoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/uveal-melanoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "uveal-melanoma" ;
  schema:name "Uveal melanoma"@en ;
  schema:alternateName "Ocular melanoma"@en, "Choroidal melanoma"@en, "Intraocular Melanoma"@en ;
  schema:description "A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."@en ;
  schema:url <https://onco.cc/cancers/uveal-melanoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Uveal_melanoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q356372> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1488>, <https://doi.org/10.1056/NEJMoa2103485>, <https://ocularmelanoma.org/> ;
  onco:tag "gap-fill", "skin", "eye", "rare" ;
  onco:related <https://onco.cc/cancers/mucosal-melanoma/>, <https://onco.cc/cancers/acral-melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/percutaneous-hepatic-perfusion/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/mri/> ;
  onco:targets <https://onco.cc/targets/gp100/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/prame/> ;
  onco:drugs <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brenetafusp/> ;
  onco:companies <https://onco.cc/companies/immunocore/>, <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/aura-biosciences/>, <https://onco.cc/companies/ionctura/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/hla-a02-restriction/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/uveal-melanoma-prognostic-markers/>, <https://onco.cc/terms/bap1-loss/>, <https://onco.cc/terms/sf3b1-mutation/> ;
  onco:trials <https://onco.cc/trials/nct07804186/>, <https://onco.cc/trials/nct07015190/>, <https://onco.cc/trials/nct06581406/>, <https://onco.cc/trials/nct05022901/>, <https://onco.cc/trials/nct05987332/>, <https://onco.cc/trials/nct06007690/> ;
  onco:journals <https://onco.cc/journals/pigment-cell-and-melanoma-research/> ;
  onco:pipeline <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/technologies/percutaneous-hepatic-perfusion/>, <https://onco.cc/drugs/brenetafusp/>, <https://onco.cc/drugs/darovasertib/> ;
  onco:standardOfCare <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/technologies/percutaneous-hepatic-perfusion/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/> .